Oral fingolimod for relapsing-remitting multiple sclerosis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 10, 2010, Pages 1777-1781

  Doggrell, Sheila A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Clinical trials; Fingolimod; Interferon 1a; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER;

ACUTE PYELONEPHRITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BLOOD PRESSURE; BRADYCARDIA; BRAIN DISEASE; BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; HEADACHE; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; INFECTION; INFLUENZA; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE SCLEROSIS; MYALGIA; NOTE; OUTCOME ASSESSMENT; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RECURRENCE RISK; RETINA MACULA EDEMA; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

EID: 77953634709     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.481671     Document Type: Note

References (11)

1. Massberg S, Von Andrian UH. Fingolimod and sphringosine-1-phosphate - modifiers of lymphocyte migration. N Engl J Med 2006;355:1088-1091
2. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140
3. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-79
4. Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3 year results. Mult Scler 2010;16:197-207
5. Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
6. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415
7. Fingolimod. Available from: http://clinicaltrials.gov/ct2/results? term=fingolimod&pg=1. [Last accessed 12 February 2010]
8. Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009;10:291-309
9. Durelli L, Verdum E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-1460
10. O'Connor P, Filippi M, Arnason B, et al. 250 ?g or 500 ?g interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-897
11. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relasing multiple sclerosis. N Engl J Med 2010;362:416-426